Charles Schwab’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-472,129
| Closed | -$8.49M | – | 3395 |
|
|
2020
Q2 | $8.49M | Buy |
472,129
+19,653
| +4% | +$273K | ﹤0.01% | 1743 |
|
|
2020
Q1 | $3.23M | Buy |
452,476
+7,611
| +2% | +$95K | ﹤0.01% | 2059 |
|
|
2019
Q4 | $10.6M | Buy |
444,865
+12,821
| +3% | +$354K | 0.01% | 1643 |
|
|
2019
Q3 | $11.6M | Buy |
432,044
+37,523
| +10% | +$1.05M | 0.01% | 1512 |
|
|
2019
Q2 | $10.7M | Buy |
394,521
+16,028
| +4% | +$503K | 0.01% | 1558 |
|
|
2019
Q1 | $13.1M | Buy |
378,493
+19,841
| +6% | +$572K | 0.01% | 1414 |
|
|
2018
Q4 | $7M | Sell |
358,652
-1,884
| -0.5% | -$38.7K | 0.01% | 1696 |
|
|
2018
Q3 | $9.6M | Buy |
360,536
+17,105
| +5% | +$558K | 0.01% | 1671 |
|
|
2018
Q2 | $13M | Buy |
343,431
+35,818
| +12% | +$1.37M | 0.01% | 1413 |
|
|
2018
Q1 | $10M | Buy |
307,613
+12,171
| +4% | +$534K | 0.01% | 1491 |
|
|
2017
Q4 | $14.4M | Buy |
295,442
+24,971
| +9% | +$1.26M | 0.01% | 1233 |
|
|
2017
Q3 | $14.6M | Buy |
270,471
+42,284
| +19% | +$2.48M | 0.01% | 1148 |
|
|
2017
Q2 | $12.8M | Buy |
228,187
+6,964
| +3% | +$279K | 0.01% | 1175 |
|
|
2017
Q1 | $8.67M | Buy |
221,223
+12,270
| +6% | +$391K | 0.01% | 1410 |
|
|
2016
Q4 | $4.69M | Buy |
208,953
+30,171
| +17% | +$589K | 0.01% | 1778 |
|
|
2016
Q3 | $4.06M | Sell |
178,782
-10,042
| -5% | -$236K | ﹤0.01% | 1785 |
|
|
2016
Q2 | $4.46M | Buy |
188,824
+3,570
| +2% | +$88.1K | 0.01% | 1636 |
|
|
2016
Q1 | $3.78M | Buy |
185,254
+4,039
| +2% | +$128K | 0.01% | 1690 |
|
|
2015
Q4 | $9.32M | Buy |
181,215
+18,428
| +11% | +$893K | 0.01% | 1079 |
|
|
2015
Q3 | $6.94M | Buy |
162,787
+8,750
| +6% | +$422K | 0.01% | 1236 |
|
|
2015
Q2 | $7.02M | Buy |
154,037
+8,137
| +6% | +$327K | 0.01% | 1312 |
|
|
2015
Q1 | $5.54M | Buy |
145,900
+35,316
| +32% | +$1.21M | 0.01% | 1438 |
|
|
2014
Q4 | $3.13M | Buy |
110,584
+19,535
| +21% | +$543K | ﹤0.01% | 1754 |
|
|
2014
Q3 | $2.3M | Buy |
91,049
+29,514
| +48% | +$777K | ﹤0.01% | 1883 |
|
|
2014
Q2 | $1.8M | Buy |
61,535
+36,456
| +145% | +$882K | ﹤0.01% | 2033 |
|
|
2014
Q1 | $650K | Buy |
25,079
+4,240
| +20% | +$113K | ﹤0.01% | 2487 |
|
|
2013
Q4 | $537K | Buy |
20,839
+648
| +3% | +$15.7K | ﹤0.01% | 2567 |
|
|
2013
Q3 | $550K | Buy |
20,191
+873
| +5% | +$20.8K | ﹤0.01% | 2514 |
|
|
2013
Q2 | $467K | Buy |
+19,318
| New | +$384K | ﹤0.01% | 2552 |
|
Charles Schwab's PTLA Position: Q3 2020 in Review
Charles Schwab sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 472,129 shares — an estimated $8.49M sold.
Charles Schwab first reported a position in PTLA in Q2 2013 and held it in 29 quarters. The position peaked at $14.6M in Q3 2017. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Charles Schwab reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Charles Schwab sold 472,129 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $8.49M.
- Charles Schwab first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
- Charles Schwab's Portola Pharmaceuticals, Inc. position peaked at $14.6M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Charles Schwab's 13F filing for Q3 2020, filed 13 Nov 2020.